Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The IPI-GLIO trial has opened to recruitment.

This is an unblinded, open labelled stratified randomised Phase II multicentre clinical trial of ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma.

Patients with newly diagnosed de-novo glioblastoma following surgery and radical radiotherapy with concomitant temozolomide will be recruited from 7 sites in the UK, and randomly allocated to receive either ipilimumab and temozolomide or temozolomide alone. The first recruiting site to open is Mount Vernon Cancer Centre in Northwood.

IPI-GLIO is sponsored by the University of Oxford and managed by the Oncology Clinical Trials Office (OCTO). The trial is funded by Bristol-Myers Squibb and The National Brain Appeal. Statistical support is provided by the Centre for Statistics in Medicine (CSM). The Chief Investigator is Dr Paul Mulholland.

Similar stories

Going straight to surgery found to be better than undergoing rehabilitation first for longstanding anterior cruciate ligament injury

New research, funded by the National Institute for Health and Care Research (NIHR), shows initial surgery to be more successful and cost effective than undergoing treatment with rehabilitation first to treat longstanding anterior cruciate ligament injury.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Emergency departments to use the FORCE pathway for wrist fractures in children

New research from the University of Oxford has shown that doctors can simplify treatment for the most common fracture in children, reducing NHS costs.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.